Our findings verified that ABZ treatment suppresses the EMT of melanoma in vitro and in vivo by inhibiting the AKT/GSK-3β pathway, resulting in decreased pGSK-3β/Ser9 (inactive form of GSK-3β) expression. The gene discussed is GSK3B; the disease is melanoma.